Mesoglycan

ApprovedSmall molecule

FFederico II University

Mesoglycan is one of 111 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

HemorrhoidActive, not recruiting

Venous ThrombosisActive, not recruiting

Metabolic SyndromeApproved

Active, not recruiting

HemorrhoidPreclinical

Active, not recruiting

Venous ThrombosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Metabolic Syndrome

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Phase 3

2 2

Kineret

SSwedish Orphan Biovitrum

Phase 3

1 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 5

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

1 6

Topamax

WWim Janssens

Phase 3

1 7

Glucophage

Boehringer Ingelheim

Phase 3

1 8

Genotropin

Comparator: Statins

1 10

Mesoglycan

FFederico II University

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemorrhoid1 trial

Mesoglycan for Acute Hemorrhoidal Disease

Unknown status·SSocieta Italiana di Chirurgia ColoRettale·N/A·NCT06101992·50 enrolled

Venous thrombosis1 trial

Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

Completed·QQuovadis Associazione·Phase 2·NCT03428711·560 enrolled

Metabolic Syndrome1 trial

Mesoglycan, Vascular Reactivity and Metabolic Syndrome

Completed·FFederico II University·Phase 4·NCT02254850·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Mesoglycan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mesoglycan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mesoglycan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federico II University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFederico II University

Mesoglycan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemorrhoid1 trial

Venous thrombosis1 trial

Metabolic Syndrome1 trial

References

Drug Info

Quick Facts

Related News